Conclusions from the histological diagnosis of low-grade intraepithelial neoplasia in Barrett's oesophagus

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 6, 2007, Pages 682-688

  Pech, Oliver ^a,c   Vieth, Michael ^b   Schmitz, Daniel ^a   Gossner, Liebwin ^a   May, Andrea ^a   Seitz, Gerhard ^b   Stolte, Manfred ^b   Ell, Christian ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b INSTITUTE OF PATHOLOGY   (Germany)

^c HSK Wiesbaden ^*  (Germany)

Author keywords

Barrett's oesophagus; Oesophageal cancer; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; OMEPRAZOLE; PANTOPRAZOLE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENDOSCOPIC SURGERY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; METAPLASIA; PHOTOTHERAPY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

AGED; BARRETT ESOPHAGUS; CARCINOMA IN SITU; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED;

EID: 34248525037     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601075803     Document Type: Article

References (33)

1. Koop H, Schepp W, Muller-Lissner S, Madisch A, Micklefield G, Messmann H, et al. Consensus conference of the DGVS on gastroesophageal reflux. Z Gastroenterol 2005;43: 163-4.
2. Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002;97:1888-95.
3. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
4. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology 2002;122:588-95.
5. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95: 1669-76.
6. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-9.
7. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
8. Rice TW, Falk GW, Achkar E, Petras RE. Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol 1993;88:1832-6.
9. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? Ann Thorac Surg 1992;54:199-204.
10. Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.
11. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001;32:368-78.
12. Vieth M, Seitz G. 50 Jahre Barrett-Ösophagus. Pathologe 2001;22:62-71.
13. Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyons: International Agency for Research on Cancer (IARC) Press; 2000. (World Health Organization classification of tumours.)
14. Pech O, Gossner L, May A, Rabenstein T, Vieth M, Stolte M, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and highgrade intraepithelial neoplasia. Gastrointest Endosc 2005; 62:24-30.
15. Schouten HJA. Statistical measurement of interobserver agreement. 1st ed. Utrecht: Elinkwijk; 1985.
16. Fleiss JL. Statistical methods for rates and proportion. 2nd ed. New York: John Wiley; 1981.
17. Altman DG. Practical statistics for medical research. 1st ed. New York: Chapman and Hall; 1991.
18. Streitz JM Jr, Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's esophagus. Does it help? J Thorac Cardiovasc Surg 1993;105:383-7.
19. Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-21.
20. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43: 216-22.
21. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
22. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br Med J 2000; 321:1252-5.
23. Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, et al. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc 2000;51:560-8.
24. Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut 2003;52:24-7.
25. Egger K, Werner M, Meining A, Ott R, Allescher HD, Hofler H, et al. Biopsy surveillance is still necessary in patients with Barrett's oesophagus despite new endoscopic imaging techniques. Gut 2003;52:18-23.
26. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
27. Morales CR, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002;360: 1587-9.
28. Wijnhoven BP, Tilanus HW, Dinjens WN. Molecular biology of Barrett's adenocarcinoma. Ann Surg 2001;233: 322-37.
29. Flejou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005;54:6-12.
30. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
31. Fennerty MB, Sampliner RE, Way D, Riddell R, Steinbronn K, Garewal HS. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. Gastroenterology 1989;97:815-20.
32. Chatelain D, Flejou JF. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch 2003;442:18-24.
33. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 2001; 96:1355-62.